BRETYLIUM TOSYLATE Drug Patent Profile

Which patents cover Bretylium Tosylate, and what generic alternatives are available?

Bretylium Tosylate is a drug marketed by Abraxis Pharm, Astrazeneca, Breckenridge, Hikma, Hospira, Intl Medication, Luitpold, Abbott, B Braun, Baxter Hlthcare, and Hospira Inc. and is included in sixteen NDAs.

The generic ingredient in BRETYLIUM TOSYLATE is bretylium tosylate. There are three drug master file entries for this compound. Additional details are available on the bretylium tosylate profile page.

Summary for BRETYLIUM TOSYLATE

US Patents:	0
Applicants:	11
NDAs:	16
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,927
DailyMed Link:	BRETYLIUM TOSYLATE at DailyMed

Medical Subject Heading (MeSH) Categories for BRETYLIUM TOSYLATE

Adrenergic Antagonists

Anti-Arrhythmia Agents

Antihypertensive Agents

US Patents and Regulatory Information for BRETYLIUM TOSYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	BRETYLIUM TOSYLATE	bretylium tosylate	INJECTABLE;INJECTION	070134-001	Apr 29, 1986		DISCN	No	No
B Braun	BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER	bretylium tosylate	INJECTABLE;INJECTION	019121-003	Apr 29, 1986		DISCN	No	No
Hikma	BRETYLIUM TOSYLATE	bretylium tosylate	INJECTABLE;INJECTION	070545-001	May 14, 1986		DISCN	No	No
Astrazeneca	BRETYLIUM TOSYLATE	bretylium tosylate	INJECTABLE;INJECTION	071152-001	Aug 10, 1987		DISCN	No	No

Bretylium Tosylate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Bretylium tosylate, an adrenergic blocking agent, exhibits a complex market dynamic primarily driven by its niche application in managing severe ventricular arrhythmias unresponsive to standard therapies. Its financial trajectory is characterized by limited market penetration, reliance on specific hospital settings, and a pricing structure reflecting its specialized use and established safety profile.

What is Bretylium Tosylate's Primary Market Application?

Bretylium tosylate's primary market application is the treatment of ventricular arrhythmias, specifically ventricular tachycardia (VT) and ventricular fibrillation (VF), that are resistant to first-line antiarrhythmic drugs and electrical cardioversion. Its mechanism of action involves an initial release of norepinephrine, followed by a blockade of adrenergic neurotransmission, which stabilizes the cardiac membrane potential and reduces ectopic activity. This makes it a critical intervention in emergent, life-threatening cardiac events within hospital critical care units.

The drug is typically administered intravenously in an emergency setting. Its use is largely confined to:

• Emergency Departments (EDs): For immediate management of cardiac arrest patients experiencing refractory VT/VF.
• Intensive Care Units (ICUs): For continuous monitoring and management of patients at high risk of or experiencing recurrent severe arrhythmias.
• Operating Rooms (ORs): During cardiac surgeries or other procedures where the risk of intraoperative arrhythmias is elevated.

The market for bretylium tosylate is therefore directly linked to the volume of severe cardiac events requiring advanced intervention and the availability of critical care infrastructure.

What is the Current Market Size and Growth Potential for Bretylium Tosylate?

The current market size for bretylium tosylate is constrained by its indication. It is not a first-line treatment, and its use is reserved for cases where other interventions have failed. This inherently limits its patient population and, consequently, its market volume. Precise global market size figures are not readily available as a standalone category in broader pharmaceutical market reports, which often group antiarrhythmics or critical care medications. However, industry estimates suggest a market value in the low tens of millions of dollars annually, a fraction of broader cardiovascular drug markets.

Growth potential is likewise limited due to several factors:

• Development of Newer Therapies: Advances in implantable cardioverter-defibrillators (ICDs), catheter ablation techniques, and novel pharmacological agents for arrhythmia management have reduced the reliance on older drugs like bretylium tosylate.
• Adverse Event Profile: While generally well-tolerated in the short term for its indicated use, bretylium tosylate can cause adverse effects such as transient hypertension, hypotension, bradycardia, and nausea. These side effects, coupled with the availability of alternatives, can steer prescribers away from its use.
• Regulatory Landscape: The drug has been available for decades, and while its efficacy in specific refractory cases is established, it has not seen significant investment in new indications or advanced formulations that would drive market expansion.

The market's growth is expected to remain modest, likely tracking the incidence of severe, refractory arrhythmias and the rate of adoption of alternative treatments. A CAGR of 1-3% over the next five years is a reasonable projection, primarily driven by demographic trends in aging populations and the prevalence of cardiovascular disease.

Who are the Key Manufacturers and Competitors in the Bretylium Tosylate Market?

The manufacturing landscape for bretylium tosylate is characterized by a few established pharmaceutical companies and potentially some generic producers. Due to its niche application and mature market status, there is limited new market entry.

Key manufacturers historically and currently include:

• Amphastar Pharmaceuticals, Inc.: A significant supplier of bretylium tosylate in the U.S. market.
• Generic Manufacturers: Various smaller pharmaceutical companies may produce generic versions of bretylium tosylate, particularly for markets where brand loyalty is less pronounced.

Competitors are not direct pharmacological alternatives for the specific refractory indications of bretylium tosylate. Instead, competition arises from:

• Alternative Treatment Modalities:
  • Implantable Cardioverter-Defibrillators (ICDs): These devices provide automatic detection and treatment of life-threatening arrhythmias and are a primary alternative for patients at high risk of sudden cardiac death.
  • Catheter Ablation: A procedure that uses radiofrequency energy or cryotherapy to destroy abnormal heart tissue causing arrhythmias.
  • Other Antiarrhythmic Drugs: While bretylium tosylate is used when others fail, drugs like amiodarone, lidocaine, and procainamide are often considered as first or second-line agents.
• Advancements in Critical Care Protocols: Evolving guidelines for managing cardiac arrest and arrhythmias can influence drug choices and the emphasis on different therapeutic approaches.

The competitive dynamic is therefore less about direct drug-to-drug competition and more about the overall treatment paradigm for severe arrhythmias.

What is the Pricing and Reimbursement Landscape for Bretylium Tosylate?

Bretylium tosylate is typically priced as a specialty drug, reflecting its limited production volume, specialized indication, and the critical nature of its use. Pricing is often determined by the cost of manufacturing, regulatory compliance, and the perceived value in life-saving scenarios.

• Wholesale Acquisition Cost (WAC): The WAC for a 500 mg vial of bretylium tosylate can range from approximately $50 to $150, depending on the manufacturer and supplier. For example, Amphastar Pharmaceuticals' bretylium tosylate for injection (500 mg/10 mL) has been listed with WACs in this range.
• Hospital Markups: Hospitals apply their own markups, which can significantly increase the final cost to the patient or insurer.
• Reimbursement: Bretylium tosylate is generally covered by most major health insurance plans and government programs like Medicare and Medicaid when administered in a medically necessary context within an inpatient hospital setting.
  • Inpatient Prospective Payment Systems (IPPS): In the U.S., the cost of bretylium tosylate is typically factored into the diagnosis-related group (DRG) payments made to hospitals under IPPS. This means the hospital receives a fixed payment for a patient's stay, regardless of the specific drugs administered, up to a certain complexity.
  • Outpatient Reimbursement: If administered in an outpatient setting (e.g., ED for stabilization), it would be reimbursed under the hospital outpatient prospective payment system (HOPPS) or other relevant physician fee schedules, often on a per-procedure or drug-specific basis.

The reimbursement landscape, while generally favorable for its indicated use, does not incentivize increased volume. The value is in its availability for emergent situations rather than chronic management, which would support higher volume sales.

What are the Key Patent and Regulatory Statuses Affecting Bretylium Tosylate's Market Exclusivity?

Bretylium tosylate is a well-established drug with a long history. Its original patents have long since expired, meaning it is in the public domain regarding composition of matter and primary use patents.

• Patent Expiry: The fundamental patents covering bretylium tosylate expired decades ago. This has allowed for generic competition.
• Current Exclusivity: Market exclusivity for bretylium tosylate is not derived from patent protection. Instead, it is based on:
  • Regulatory Exclusivity: While not common for older drugs, any new process patents for manufacturing or formulation could offer limited protection. However, no significant new patents of this nature are currently driving market exclusivity.
  • Established Supply Chains and FDA Approval: Manufacturers maintain FDA approval for their specific formulations and manufacturing processes. Disruption of these established supply chains and approvals is a barrier to entry for new generic manufacturers.
  • "Orphan Drug" Status: Bretylium tosylate does not qualify for orphan drug status as its indications do not meet the criteria for rare diseases.
• Regulatory Status: The drug is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) for its indicated uses. It is listed in pharmacopeias (e.g., USP) with approved specifications. Ongoing regulatory requirements pertain to good manufacturing practices (GMP), quality control, and pharmacovigilance.

The lack of patent protection means that pricing power is limited by the presence of generics. However, the niche indication and specialized distribution channels allow manufacturers to maintain a stable, albeit small, revenue stream.

What are the Future Trends and Potential Disruptions for Bretylium Tosylate?

The future trajectory of bretylium tosylate is likely to be characterized by continued niche application and gradual market erosion, punctuated by potential, though unlikely, disruptive events.

Key Future Trends:

• Continued Reliance in Refractory Cases: Bretylium tosylate will likely remain a treatment option for severe ventricular arrhythmias that do not respond to other therapies, particularly in hospital settings where emergency protocols are well-established.
• Demographic Influence: An aging global population and the increasing prevalence of cardiovascular diseases will likely sustain a baseline demand for critical care medications, including bretylium tosylate.
• Focus on Cost-Effectiveness: As healthcare systems globally face cost pressures, the cost-effectiveness of older, generic drugs like bretylium tosylate may become a more significant factor in purchasing decisions, potentially favoring generic suppliers.

Potential Disruptions:

• Development of Novel Pharmacological Agents: Breakthroughs in antiarrhythmic drug development could lead to new therapies that are more effective or have superior safety profiles for refractory arrhythmias, potentially displacing bretylium tosylate.
• Technological Advancements in Device Therapy: Further innovations in ICDs, wearable cardiac devices, and advanced ablation techniques could reduce the incidence of severe, refractory arrhythmias requiring pharmacological intervention.
• Changes in Clinical Guidelines: Revisions to major cardiology guidelines (e.g., ACC/AHA guidelines for management of arrhythmias) could de-emphasize or remove bretylium tosylate from recommended treatment algorithms, leading to a significant reduction in its use.
• Supply Chain Vulnerabilities: While unlikely for a mature product, any significant disruption to manufacturing or the supply chain from a key manufacturer could create short-term market shortages, potentially leading to increased prices or urgent searches for alternative suppliers.

The market is mature, and significant growth is not anticipated. The primary risk to its existing market share comes from innovation in alternative therapeutic approaches rather than direct competition from similar pharmacological agents.

Key Takeaways

• Bretylium tosylate is a critical care drug for refractory ventricular arrhythmias, with a market size in the low tens of millions of dollars.
• Its growth potential is limited by alternative therapies like ICDs, catheter ablation, and newer antiarrhythmics, projecting a modest CAGR of 1-3%.
• Key manufacturers include Amphastar Pharmaceuticals and various generic producers, with competition stemming from alternative treatment modalities rather than direct drug alternatives.
• Pricing reflects its specialty status ($50-$150 per vial WAC), with reimbursement integrated into inpatient hospital payments (DRGs) and outpatient coding.
• Original patents have expired; market exclusivity relies on established regulatory approvals and supply chains, not patent protection.
• Future trends point to continued niche use, influenced by demographics and cost-effectiveness, while potential disruptions lie in novel pharmacological agents and advanced device therapies.

Frequently Asked Questions

1. What is the primary mechanism of action for bretylium tosylate? Bretylium tosylate initially causes a release of norepinephrine, leading to a transient increase in blood pressure and heart rate, followed by blockade of adrenergic neurotransmission. This blockade reduces sympathetic nerve activity to the heart, stabilizing the cardiac membrane potential and decreasing ectopic beats.

2. Is bretylium tosylate used for chronic arrhythmia management? No, bretylium tosylate is not used for chronic arrhythmia management. Its application is restricted to acute, life-threatening ventricular arrhythmias (ventricular tachycardia and ventricular fibrillation) that are unresponsive to first-line treatments.

3. What are the most common side effects associated with bretylium tosylate administration? The most common side effects include transient hypertension and hypotension, bradycardia, nausea, vomiting, and dizziness. These effects are often managed by dose adjustment or supportive care during acute treatment.

4. How does bretylium tosylate compare to amiodarone in treating ventricular arrhythmias? Amiodarone is often considered a first or second-line agent for both ventricular and supraventricular arrhythmias, with a broader range of applications and a different, more complex long-term side effect profile. Bretylium tosylate is reserved for refractory ventricular arrhythmias where amiodarone or other agents have failed. Their efficacy and risk profiles differ, making them not directly interchangeable.

5. Can bretylium tosylate be administered outside of a hospital setting? Due to its administration route (intravenous), the potential for rapid side effects requiring immediate medical intervention, and its indication for severe, life-threatening arrhythmias, bretylium tosylate is almost exclusively administered within hospital critical care settings such as emergency departments or intensive care units.

Citations

[1] Amphastar Pharmaceuticals, Inc. (n.d.). Bretylium Tosylate for Injection. Retrieved from Amphastar Pharmaceuticals official product information or distributor websites.

[2] U.S. Food & Drug Administration. (n.d.). Drug Approval Process and Information. Retrieved from www.fda.gov.

[3] American Heart Association. (2020). 2020 AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 142(16_suppl_1), S1-S219.

[4] Lacy, C. F., Armstrong, L. L., Kolonel, P. G., & Shimp, L. A. (2017). Lexicomp Drug Information Handbook. Lexicomp. (Specific edition and page numbers would vary based on access).

[5] Various pharmaceutical market research reports and analyses from sources such as IQVIA, Clarivate Analytics, and Evaluate Pharma (specific reports and dates would vary based on access and the exact data point).